Payment overview · 2025
General Payments
$3,068.24
42 reported records · 7 companies
Healthcare provider profile · identity verified
Dennis Suarez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MAYAGUEZ, PR · NPI 1194785477
Verified facts
What the public records show
CMS Open Payments records show Dennis Suarez, MD received $3,068.24 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 69.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Enbrel, Hadlima, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Organon LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HADLIMA as an associated drug or biological on 6403 records involving 3486 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Hadlima by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $2,126.21 | 69.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $490.06 | 16.0% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $192.30 | 6.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $106.21 | 3.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.49 | 2.7% | 4 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $42.10 | 1.4% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.87 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,750.00 | 1 |
| Food and Beverage | $1,318.24 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $2,126.21 | 9 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $236.21 | 8 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $192.30 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $183.21 | 9 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $181.85 | 8 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $110.73 | 8 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $106.21 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.20 | 6 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $83.49 | 4 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| AMJEVITA Normalized: amjevita |
Biological | Amgen Inc. | $4.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENBREL enbrel |
2025 | Enbrel | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| HADLIMA hadlima |
2025 | Hadlima | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
96 | 27 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
58 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Organon LLC Exact reporting entity; no affiliate inference |
2025 | HADLIMA open payments reported associated product |
CMS Open Payments — General Payments 6403 supporting records · 3486 recipient NPIs · example record 1237634340 |
Hadlima · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 2429 | 414 |
| Prednisone | Prednisone | 1394 | 241 |
| Tizanidine Hcl | Tizanidine Hcl | 1182 | 274 |
| Methotrexate | Methotrexate Sodium | 1076 | 153 |
| Famotidine | Famotidine | 848 | 176 |
| Alendronate Sodium | Alendronate Sodium | 839 | 174 |
| Pregabalin | Pregabalin | 743 | 105 |
| Diclofenac Sodium | Diclofenac Sodium | 715 | 178 |
| Nabumetone | Nabumetone | 704 | 174 |
| Meloxicam | Meloxicam | 672 | 148 |
| Risedronate Sodium | Risedronate Sodium | 403 | 84 |
| Diclofenac Potassium | Diclofenac Potassium | 331 | 77 |
| Leflunomide | Leflunomide | 317 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 57 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 284 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 261 | 60 |
| Omeprazole | Omeprazole | 256 | 54 |
| Celecoxib | Celecoxib | 250 | 54 |
| Enbrel Sureclick | Etanercept | 243 | 27 |
| Losartan Potassium | Losartan Potassium | 222 | 47 |
| Orencia Clickject | Abatacept | 201 | 20 |
| Etodolac Er | Etodolac | 196 | 43 |
| Allopurinol | Allopurinol | 193 | 33 |
| Humira(Cf) Pen | Adalimumab | 179 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 166 | 36 |
| Ibuprofen | Ibuprofen | 144 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 113 | 29 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 113 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 105 | 19 |
| Colchicine | Colchicine | 103 | 21 |
| Tramadol Hcl | Tramadol Hcl | 103 | 71 |
| Cevimeline Hcl | Cevimeline Hcl | 97 | 16 |
| Synthroid | Levothyroxine Sodium | 96 | 27 |
| Hadlima(Cf) Pushtouch | Adalimumab-Bwwd | 91 | suppressed |
| Baclofen | Baclofen | 88 | 23 |
| Actemra Actpen | Tocilizumab | 87 | suppressed |
| Clonazepam | Clonazepam | 87 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 87 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 17 |
| Savella | Milnacipran Hcl | 82 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 79 | 21 |
| Naproxen | Naproxen | 78 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 19 |
| Methylprednisolone | Methylprednisolone | 75 | 16 |
| Simvastatin | Simvastatin | 68 | 18 |
| Sulindac | Sulindac | 68 | 15 |
| Etodolac | Etodolac | 66 | 13 |
| Metformin Hcl | Metformin Hcl | 66 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 11 |
| Lidocaine | Lidocaine | 59 | 15 |
| Naproxen Sodium | Naproxen Sodium | 58 | 18 |
| Prolia | Denosumab | 58 | 41 |
| Xeljanz Xr | Tofacitinib Citrate | 57 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 55 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 54 | 14 |
| Enbrel | Etanercept | 53 | suppressed |
| Irbesartan | Irbesartan | 53 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Montelukast Sodium | Montelukast Sodium | 52 | 12 |
| Azathioprine | Azathioprine | 50 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 50 | 12 |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 50 | 24 |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Meclizine Hcl | Meclizine Hcl | 47 | suppressed |
| Ciclopirox | Ciclopirox | 44 | 17 |
| Enbrel Mini | Etanercept | 44 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Lansoprazole | Lansoprazole | 42 | 12 |
| Sulfasalazine Dr | Sulfasalazine | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 18 |
| Simponi | Golimumab | 41 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 41 | 30 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 38 | suppressed |
| Tymlos | Abaloparatide | 38 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 35 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Orencia | Abatacept | 35 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 32 | suppressed |
| Hadlima Pushtouch | Adalimumab-Bwwd | 32 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 12 |
| Carvedilol | Carvedilol | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 13 |
| Levoxyl | Levothyroxine Sodium | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Desonide | Desonide | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Rinvoq | Upadacitinib | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Metaxalone | Metaxalone | 23 | suppressed |
| Amjevita(Cf) Autoinjector | Adalimumab-Atto | 22 | suppressed |
| Cosentyx Unoready Pen | Secukinumab | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Humira(Cf) | Adalimumab | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Lisinopril | Lisinopril | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Hadlima | Adalimumab-Bwwd | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Teriparatide | Teriparatide | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,068.24 · 42 records | ABBVIE INC. | AMJEVITA, BENLYSTA, COSENTYX, ENBREL, EVENITY, HADLIMA, KRYSTEXXA, OTEZLA, PURIFIED CORTROPHIN GEL, RENFLEXIS, RINVOQ, SAPHNELO, SKYRIZI, TAVNEOS | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Enbrel play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error